Focus: Verity Pharmaceuticals is a specialty pharma company focused on genitourinary therapies, headquartered in Ewing, NJ with a portfolio anchored by the legacy product TRELSTAR. The company operates as a smaller, revenue-dependent player in a niche therapeutic area.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Verity Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Verity Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Verity Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Franchise anchor driving 87% of company revenue; faces patent cliff in 2029-2030, creating existential revenue cliff for the organization.
Second-largest product with $1M revenue; loses exclusivity in 2027, compounding portfolio transition pressure.
Oral testosterone formulation with longest patent runway (until 2041); smallest contributor but most durable asset.
Duplicate entry for TRELSTAR formulation; reinforces portfolio concentration on single drug asset.
Duplicate entry for TRELSTAR formulation; reinforces portfolio concentration on single drug asset.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub